Publications by authors named "A Briault"

Antibody-mediated rejection (AMR) has been recognized as a significant cause of acute and chronic lung allograft dysfunction after lung transplantation. Some treatments, eculizumab, an anti-complement (C)5 component monoclonal antibody (Mab), seem to have a promising effect in the management of some patients with AMR. We present two patients with acute AMR after lung transplantation who received the anti-C5 Mab therapy.

View Article and Find Full Text PDF

Standard immunosuppressive therapy for lung transplant recipients combines a calcineurin inhibitor, an antimetabolite, and corticosteroids. In an observational, retrospective, monocentric study, we sought to compare the development of chronic lung allograft dysfunction (CLAD) between 37 patients who received this standard therapy (triple-therapy group) and 59 patients who received the mammalian target of rapamycin (mTOR) inhibitor everolimus in addition to the standard therapy (quadruple-therapy group). In the quadruple-therapy group, the time elapsed from transplantation to everolimus introduction (median [25th-75th percentile]) was 12 [7-25] months.

View Article and Find Full Text PDF

Mastering and monitoring immunosuppressant concentrations is central to the care of lung transplant patients and involves multiple stakeholders. The objective is to conduct a risk analysis to evaluate the impact of various actions taken. The lung transplantation team was convened to carry out a failure mode effect analysis.

View Article and Find Full Text PDF

Background: Self-expandable uncovered metallic stents (SEUMS) have been used in benign tracheobronchial stenosis. Stent complications may require risky removal due to SEUMS integration in the tracheobronchial wall. Our study aims to report techniques, including a novel one, and outcomes of SEUMS removal by rigid bronchoscopy.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the incidence and treatment of malignant central airway obstruction (MCAO) in patients with metastatic non-bronchogenic solid cancers (NBC), revealing that 18% of a large cohort experienced this complication.
  • It identifies key prognostic factors influencing survival post-therapeutic bronchoscopy (TB), such as histology, performance status, and previous treatments.
  • The findings suggest that TB effectively alleviates symptoms and prolongs survival for these patients, highlighting the need for timely referrals for bronchoscopic interventions.
View Article and Find Full Text PDF